SYS6002

DRUG5 trials

Sponsors

CSPC Megalith Biopharmaceutical Co.,Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Advanced Solid TumorsAdvanced Urothelial CarcinomaCervical CancerHead and Neck Squamous Cell CarcinomaUrothelial Carcinoma

Phase 1

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

RecruitingNCT07241936

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Solid Tumors

Start: 2025-11-13End: 2028-10-30Target: 444Updated: 2025-11-28

Phase 2

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

Not yet recruitingNCT06989671

CSPC Megalith Biopharmaceutical Co.,Ltd.Head and Neck Squamous Cell Carcinoma

Start: 2025-08-30End: 2028-07-30Target: 430Updated: 2025-08-27

SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma

Not yet recruitingNCT07374549

CSPC Megalith Biopharmaceutical Co.,Ltd.Advanced Urothelial Carcinoma

Start: 2026-06-20End: 2028-12-01Target: 100Updated: 2026-01-29

Phase 3

SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Not yet recruitingNCT07230626

CSPC Megalith Biopharmaceutical Co.,Ltd.Cervical Cancer

Start: 2025-11-20End: 2028-07-01Target: 412Updated: 2025-11-17

SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Not yet recruitingNCT07526792

CSPC Megalith Biopharmaceutical Co.,Ltd.Urothelial Carcinoma

Start: 2026-06-20End: 2029-12-01Target: 406Updated: 2026-04-13